1530 Stock Overview
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
3SBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$11.50 |
| 52 Week High | HK$13.98 |
| 52 Week Low | HK$5.47 |
| Beta | 0.67 |
| 1 Month Change | -7.26% |
| 3 Month Change | 80.25% |
| 1 Year Change | 74.51% |
| 3 Year Change | 107.58% |
| 5 Year Change | 16.75% |
| Change since IPO | 22.99% |
Recent News & Updates
Solid Earnings Reflect 3SBio's (HKG:1530) Strength As A Business
May 07
3SBio Inc. (HKG:1530) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected
Apr 24Recent updates
Solid Earnings Reflect 3SBio's (HKG:1530) Strength As A Business
May 073SBio Inc. (HKG:1530) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected
Apr 243SBio (HKG:1530) Has Announced A Dividend Of CN¥0.25
Apr 173SBio (HKG:1530) Will Pay A Dividend Of CN¥0.25
Mar 313SBio Inc. (HKG:1530) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$10.80
Mar 303SBio Inc. (HKG:1530) Soars 27% But It's A Story Of Risk Vs Reward
Mar 103SBio Inc. (HKG:1530) Screens Well But There Might Be A Catch
Jan 173SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Oct 083SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce
Oct 07We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 26Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being
Jun 19There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price
May 21Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now
Jan 26These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely
Dec 30Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Dec 11Is 3SBio (HKG:1530) A Risky Investment?
Sep 12Calculating The Fair Value Of 3SBio Inc. (HKG:1530)
Aug 07With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case
Jul 193SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
Apr 13Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Feb 27Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?
Jan 17Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?
Nov 24We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Oct 213SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate
Oct 04Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?
Apr 21We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Mar 31We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Dec 09An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued
Nov 21We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 103SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate
Aug 223SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price
May 21Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16Shareholder Returns
| 1530 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.1% | -9.6% | 3.4% |
| 1Y | 74.5% | 36.6% | 13.0% |
Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned 36.6% over the past year.
Return vs Market: 1530 exceeded the Hong Kong Market which returned 13% over the past year.
Price Volatility
| 1530 volatility | |
|---|---|
| 1530 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1530's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1530's weekly volatility has increased from 8% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,577 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC external medicine for treating hair loss; and SPARIN, an injectable low-molecular-weight heparin calcium.
3SBio Inc. Fundamentals Summary
| 1530 fundamental statistics | |
|---|---|
| Market cap | HK$27.12b |
| Earnings (TTM) | HK$2.26b |
| Revenue (TTM) | HK$9.86b |
12.0x
P/E Ratio2.8x
P/S RatioIs 1530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1530 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.11b |
| Cost of Revenue | CN¥1.28b |
| Gross Profit | CN¥7.83b |
| Other Expenses | CN¥5.74b |
| Earnings | CN¥2.09b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 85.95% |
| Net Profit Margin | 22.95% |
| Debt/Equity Ratio | 19.4% |
How did 1530 perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield27%
Payout RatioDoes 1530 pay a reliable dividends?
See 1530 dividend history and benchmarks| 3SBio dividend dates | |
|---|---|
| Ex Dividend Date | Jul 21 2025 |
| Dividend Pay Date | Aug 15 2025 |
| Days until Ex dividend | 68 days |
| Days until Dividend pay date | 93 days |
Does 1530 pay a reliable dividends?
See 1530 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 21:09 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
3SBio Inc. is covered by 34 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Capstone Investments |
| Bo Yu | China International Capital Corporation Limited |
| Zhuhong Chen | China Merchants Securities (HK) Co., Ltd |